Use of transcatheter heart valves for a valve-in-valve implantation in patients with degenerated aortic bioprosthesis: Technical considerations and results

Vinayak Bapat, FRCS CTh, Rizwan Attia, MRCS, Simon Redwood, FRCP, Jane Hancock, FRCP, Karen Wilson, MS, Christopher Young, FRCS CTh, and Martyn Thomas, FRCP

Objective: Transcatheter aortic valve implantation has been used to treat high-risk patients with bioprosthetic valve degeneration (valve-in-valve). We report our experience with transcatheter aortic valve implantation in the treatment of degenerated biologic aortic valve prostheses and discuss factors that can influence the outcome.

Methods: From February 2009 to October 2011, 278 patients underwent transcatheter aortic valve implantation, of whom 23 underwent a valve-in-valve procedure with the Edwards Sapien valve to treat a failing bioprosthesis in the aortic position. Eight of these valves were stentless bioprostheses. Thirteen patients had valve failure resulting predominantly from stenosis, and the remaining resulting from regurgitation.

Results: Mean age was 76.9 ± 14.4 years. The mean logistic EuroSCORE was 31.8% ± 20.3% and the Society of Thoracic Surgeons score was 7.6% ± 5.4%. All patients were New York Heart Association class III or IV. The majority of the operations (21/23) were performed via the transapical route. Procedural success was 100%, although 1 patient with a degenerated homograft needed immediate placement of a second valve because of low placement of the first. The reduction in the mean gradient was 31.2 ± 17.06 mm Hg to 9.13 ± 4.9 mm Hg. In those patients with predominant aortic regurgitation (9/23), reduction in aortic regurgitation was achieved in all. The median length of stay was 11.7 days (range, 3-44 days). In-hospital and/or 30-day mortality was 0%.

Conclusions: Valve-in-valve is a safe and feasible alternative to treat high-risk patients with failing aortic bioprostheses. The early results are excellent, with improvement seen in hemodynamics. (J Thorac Cardiovasc Surg 2012;144:1372-80)

Transcatheter aortic valve implantation (TAVI) has emerged as a viable treatment modality for patients with severe native aortic valve stenosis and multiple comorbidities that would typically preclude them from surgery.1-3 The “on-label” indication for TAVI using the Edwards Sapien device (Edwards Lifesciences, Irvine, Calif) is native calcific aortic stenosis in a tricuspid aortic valve in absence of any other prosthesis in the heart.2,3 Novel applications of TAVI, such as use in aortic stenosis in a bicuspid valve,4 TAVI in the presence of mitral prosthesis,5 and valve-in-valve (VIV),6,16 have gathered momentum as a result of clinical need. Although small in number when compared with the number of TAVI implants, the number of VIV procedures has increased rapidly in 2011. In addition to the case reports, a few case series from single institutions and collaborative series’ from multiple institutions have demonstrated feasibility and acceptable early results in selected patients.6-16 The majority of the experience in VIV has been in the treatment of failing stented bioprosthetic aortic valves and, to date, there are only isolated reports of the use of TAVI in the setting of a failing stentless bioprostheses.9,10,13

The concept and initial results have been encouraging. VIV procedures are currently undertaken if the conventional redo operation is deemed high risk. We present our VIV experience in 23 consecutive patients using the Edwards transcatheter valve (Sapien and Sapien XT). We also discuss the technical considerations and current limitations of the VIV procedure.

METHODS

Patient Characteristics

Between February 2009 and October 2011 we performed 23 VIV TAVI procedures for aortic bioprosthetic degeneration using the Edwards Sapien and Sapien XT valve. Mean patient age was 76.9 ± 14.4 years (range, 29-92 years). The male-to-female ratio was 1.3:1. The mode of presentation was either severe aortic valve regurgitation (n = 9) or stenosis (n = 14). The mean logistic EuroSCORE (LES) was 31.8% ± 20.3% and the mean Society of Thoracic Surgeons score was 7.6% ± 5.4%. Patients were discussed in a multidisciplinary team meeting (MDT) comprised of 2 cardiac surgeons, 2 intervention cardiologists, 1 noninvasive cardiologist, and 1

Copyright © 2012 by The American Association for Thoracic Surgery

http://dx.doi.org/10.1016/j.jtcvs.2012.07.104

From the Department of Cardiothoracic Surgery and Cardiology, Guys and St. Thomas’ Hospital, London, United Kingdom.

Disclosures: Authors have nothing to disclose with regard to commercial support.

Read at the 92nd Annual Meeting of The American Association for Thoracic Surgery, San Francisco, California, April 28-May 2, 2012.

Received for publication April 25, 2012; revisions received June 17, 2012; accepted for publication July 26, 2012.

Address for reprint: Vinayak Bapat, FRCS CTh, Department of Cardiothoracic Surgery, 6th Floor East Wing, St. Thomas’ Hospital, Westminster Bridge Rd, London SW21 7JB, UK (E-mail: vnbapat@yahoo.com).

0022-5223/$36.00

Copyright © 2012 by The American Association for Thoracic Surgery

http://dx.doi.org/10.1016/j.jtcvs.2012.07.104

0022-5223/$36.00
cardiac anesthetist. Patients were also discussed with a respiratory physician and a geriatrician when indicated. These patients were thought to be at high risk for conventional open aortic valve replacement and hence were accepted for TAVI. Patients’ baseline characteristics are listed in Table 1. Of these 23 patients, 15 patients had a stented bioprosthesis and 8 patients had a stentless aortic bioprosthesis. The mean length of time from the previous aortic valve procedure for stented valves and stentless valves was 9.4 ± 3.86 years (range, 4-19 years) and 14 ± 6.21 years, respectively. Details of various degenerated bioprostheses are listed in Table 2.

Preoperative Investigations

Three patients had undergone at least 3 open surgical procedures. Other than routine investigations, the preoperative diagnostic workup included a transthoracic echocardiogram, coronary and peripheral angiography, a noncontrast computed tomographic (CT) scan of the aorta, a respiratory function test, and a carotid Doppler examination. In addition, a preoperative transesophageal echocardiogram (TEE) was carried out in all patients with a stentless aortic bioprosthesis to determine the exact aortic annular diameter. Infective endocarditis was ruled out in all patients, which is especially important when the mode of valve failure is regurgitation. Prior operative notes were consulted when available to obtain details of the type of valve implanted, the valve size, and the surgical technique used.

Operative Technique

The procedures were all performed in a cardiac catheterization laboratory by a combined team of cardiac surgeons, cardiologists, and anesthesiologists. A perfusionist was also always present with an assembled heart–lung machine. The approach for TAVI was either transfemoral (TF) or transapical (TA). The choice of the approach was dependent on the type of bioprosthesis in situ and the size of the femoral arteries. We preferred the TA approach in all cases of stented bioprostheses and the type of bioprosthesis in situ and the size of the femoral arteries. The heart–lung machine. The approach for TAVI was either transfemoral

Abbreviations and Acronyms

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>BAV</td>
<td>balloon aortic valvuloplasty</td>
</tr>
<tr>
<td>CT</td>
<td>computed tomographic</td>
</tr>
<tr>
<td>LES</td>
<td>logistics Euroscore</td>
</tr>
<tr>
<td>MDT</td>
<td>multidisciplinary team meeting</td>
</tr>
<tr>
<td>TA</td>
<td>transapical</td>
</tr>
<tr>
<td>TAVI</td>
<td>transcatheter aortic valve implantation</td>
</tr>
<tr>
<td>TEE</td>
<td>transesophageal echocardiogram</td>
</tr>
<tr>
<td>TF</td>
<td>transfemoral</td>
</tr>
<tr>
<td>VIV</td>
<td>valve-in-valve</td>
</tr>
</tbody>
</table>

RESULTS

Intraoperative

The procedural success rate was 100%. One patient with a degenerated homograft had an immediate second VIV implant after low placement of the first valve resulting from difficulty in visualizing the level of the annulus. One patient had a right ventricular perforation from 1 of the transvenous pacing wires used during the procedure. This was diagnosed immediately as a pericardial effusion on the TEE and was repaired without the use of cardiopulmonary bypass. In 15 patients, a 23-mm Sapien valve was implanted (13 stented valves and 2 stentless valves), in 6 patients a 26-mm valve was implanted (2 stented valves and 4 stentless valves), and in 2 patients a 29-mm valve was implanted (both stented valves). The sizes of in situ bioprostheses and the Sapien valve used are listed in Tables 2 and 3. The mean procedure time was 89 ± 28.5 minutes (range, 44-135 minutes). The mean fluoroscopy time was 11.4 ± 4.9 minutes (range, 5.5-18 minutes). The mean volume of
contrast medium used during the procedure was 52 mL (range, 0-150 mL). More contrast was used when treating stentless valves. After valve implantation, the mean peak gradient and mean gradient decreased from 54.54/C629.2 mm Hg to 16.5/C69.8 mm Hg and 31.2/C617.06 mm Hg, respectively. Five patients had mild paravalvular aortic regurgitation postimplantation whereas the other 18 patients had no regurgitation.

Postoperative
During the early postoperative course, there were 3 significant complications: 1 patient required reoperation for venous bleeding from the epicardium after having the procedure via the TA approach (4.35%), 1 patient developed transient right-sided weakness on postoperative day 1 that later resolved completely (4.35%) and 4 patients developed acute kidney injury necessitating temporary hemodialysis (17.39%). There were no postoperative myocardial infarctions, no indications for postoperative pacemaker insertion, and no wound complications. The median intensive care unit length of stay was 1 day (range, 0.5-13 days) and median length of stay was 11 days (range, 3-44 days). There was no in-hospital and/or 30-day mortality. All patients were New York Heart Association class II at the time of discharge.

Follow-up Data
There were no early or late valve reinterventions or open conversions. The mean follow-up was 8.1 months (range,
6-24 months). There were 3 late deaths during follow-up period. One death was the result of rupture of a large abdominal aortic aneurysm on day 46. The patient had undergone a VIV procedure successfully and was awaiting a stent procedure for the abdominal aortic aneurysm. The second death was a result of respiratory failure on day 63, which was precipitated by pneumonia. The third death was the result of a massive gastric bleed on day 105. This patient was on single-agent antiplatelet therapy.

DISCUSSION

During the past decade, there has been an increase in valve procedures, especially aortic valve replacement. Newer generation bioprostheses are reported to last longer, and hence the age bar for implantation of a bioprosthesis has been lowered.20 It is conceivable that the majority of these patients are going to outlive the bioprosthesis and will present for redo aortic valve replacement in the future. Refinements in operative technique and postoperative management have led to low morbidity and mortality rates.21 The operative mortality for an elective redo aortic valve surgery is reported to range from 2% to 7%, but this percentage can increase to more than 30% in high-risk patients.21 Furthermore, redo operations are also associated with increasing morbidity and prolonged recovery.21 For this subset of patients, VIV TAVI represents a less invasive alternative to conventional redo surgery.

In 2007, Wenaweser and colleagues6 reported the first successful application of VIV TAVI using a 26-mm CoreValve (Medtronic Ltd, Minn) in the treatment of a degenerated bioprosthesis (23-mm Mitraflow) in the aortic position. Since then, multiple authors have demonstrated that VIV TAVI is technically feasible and safe, with excellent early results and low mortality using either the Sapien valve or the CoreValve.7-16 Immediate hemodynamic improvement and early results have been encouraging in this cohort of patients. The first multicenter experience using the Sapien valve was reported by Webb and associates,7 who reported 24 high-risk patients with an LES of 30.4%/9.7% and a Society of Thoracic Surgeons score of 10.0%/5.2%. Implantation was successful in all but 1 patient, in whom the valve embolized into the distal aorta. There were no procedural deaths, and 30-day mortality was 4.2%. Gotzmann and coworkers8 reported the first series using the self-expanding CoreValve. The average LES in their 5 patients was >30%. Procedural success was 100% with mild perivalvular/paravalvular leak in 2 of 5 patients and a reduction in the peak gradient from 67.6 ± 19.3 mm Hg to 21.2 ± 11.4 mm Hg. Pacemaker requirements have been reported to be minimal and were none in our series.7,8,13-15 Experience in VIV for stentless bioprostheses is comparatively less.13 Traditionally, the use of TAVI has been contraindicated in patients with aortic regurgitation, which is the primary mode of failure of stentless valves. However, the inherent bulk of the stentless valve and the sutures used for its implantation can provide anchoring for the new stented valve. Nevertheless, VIV in a stentless valve is a more challenging procedure. Choice of valve used is operator dependent. Of the 17 patients reported in the literature and our 8 patients, 18 patients were treated with the Sapien valve and 7 with the CoreValve.13

---

**TABLE 3. Stentless valve types and their implantation options**

<table>
<thead>
<tr>
<th>Valve name (manufacturer)</th>
<th>Implantation technique</th>
</tr>
</thead>
<tbody>
<tr>
<td>Toronto SPV (St. Jude Medical)</td>
<td>Subcoronary</td>
</tr>
<tr>
<td>Toronto Root (St. Jude Medical)</td>
<td>Full root, inclusion root</td>
</tr>
<tr>
<td>Freestyle (Medtronic)</td>
<td>Full root, inclusion root,</td>
</tr>
<tr>
<td></td>
<td>subcoronary</td>
</tr>
<tr>
<td>Prima Plus (Edwards LifeSciences)</td>
<td>Full root, inclusion root,</td>
</tr>
<tr>
<td></td>
<td>subcoronary</td>
</tr>
<tr>
<td>CryoLife-O’Brien (CryoLife)</td>
<td>Subcoronary</td>
</tr>
<tr>
<td>Elan (AorTech)</td>
<td>Subcoronary</td>
</tr>
<tr>
<td>Shellhigh Superstentless (Shellhigh)</td>
<td>Subcoronary</td>
</tr>
<tr>
<td>Shellhigh Bioconduit (Shellhigh)</td>
<td>Full root</td>
</tr>
<tr>
<td>Biocor PSB/SJM (St. Jude Medical)</td>
<td>Subcoronary</td>
</tr>
<tr>
<td>Pericarbon Freedom (Sorin)</td>
<td>Subcoronary</td>
</tr>
<tr>
<td>3F Aortic Bioprosthesis (3F Therapeutics)</td>
<td>Subcoronary</td>
</tr>
</tbody>
</table>
Successful outcome of the VIV procedure is dependent on patient selection, understanding the design of the degenerated bioprosthesis, anticipation of complications, and procedural planning. It is important that the team is experienced in TAVI before undertaking a VIV procedure. We discuss here some important aspects in planning and performing a VIV case.

Patient Selection
In our center, we consider the VIV procedure only when the patient is considered high risk for a conventional redo procedure. Each patient is discussed at our MDT. Certain technical and design characteristics of the bioprosthetic valve in situ are studied before accepting the patient for a VIV procedure. We use the Edwards Sapien device, which currently is only available in 3 sizes: 23 mm, 26 mm, and 29 mm. The annulus range in which it is used to treat a native aortic stenosis is 18 to 27 mm. Thus, using this device, a surgeon can only perform VIV in bioprostheses valves with internal diameters ranging from 18 to 27 mm. Similar size limitations apply for the CoreValve. If used in valves with a larger internal diameter, it can result in valve embolization. If used for a smaller diameter bioprosthesis, it would lead to underexpansion of the Sapien valve, which may interefere with its short-term and long-term hemodynamic performance and a high residual gradient. Pasic and associates, in one of the earliest VIV series, felt that the VIV procedure in these patients should only be undertaken as a last resort. Although many reports have since emerged demonstrating successful results in smaller valves, including 1 patient in our series with stent internal diameter <18 mm, we concur with them and accept these patients only when the reoperation risks are prohibitive. One also must be aware that the internal diameter of the bioprosthetic valve provided by the manufacturer is of the “stent” without leaflets. Thus, in reality, the actual internal diameter is smaller than provided.

Route for VIV
In the initial reports of VIV, the TA route was preferred because it allowed better control and fine adjustment during valve placement. Furthermore, crossing of a stented bioprosthesis was much easier via the TA route and is independent of the size of the peripheral vessels. However, in centers in which both Sapien and CoreValve devices are used routinely, the choice seems to depend on the access route—CoreValve for a TF approach and Sapien for a TA approach. With the current modifications to the TF delivery systems for the Sapien valve (ie, Novoflex delivery system), which include a nosecone at the tip and minimal movement of the device during valve deployment, the TF route is being used increasingly for VIV procedures for stented bioprostheses. The choice, however, depends entirely on the comfort of the team and its experience with a particular delivery system. We have used the TA route for stented valves, in patients with stentless valves when their peripheral arteries were not suitable for TF, and when the aortic root anatomy was challenging (eg, a horizontal aorta).

Valve Design and Characteristics
It is of paramount importance to familiarize oneself with the design, fluoroscopic appearance, and implantation technique of the degenerated bioprosthetic valve for a successful outcome and to minimize complications such as malpositioning, valve embolization, and coronary obstruction.

Stented Valves
Internal diameter. From the standpoint of VIV implantation, it is the internal diameter of the failed valve that is most relevant. We have published a complete chart of internal diameter measurements of the majority of commercially available bioprosthetic valves. It should be kept in mind that the disease process affecting the implanted valve can have varying effects on the internal diameter, including calcification and/or thickening of the tissue leaflets and pannus in growth. Pannus and calcification can reduce the internal diameter of the stent significantly. Hence, CT scanning and TEE are an important adjunct to available internal diameter in choosing the correct size of the TAVI valve by identifying presence of calcification and pannus, respectively. This fact is highlighted in the series published by Webb and colleagues, in which 2 patients had a degenerated 25-mm Carpentier-Edwards Perimount valve (internal stent diameter, 24 mm). Both were treated successfully but 1 was treated with a 23-mm Sapien valve most likely because of pannus ingrowth and the other with a 26-mm Sapien.

Fluoroscopic appearance. We have recently published a guide to fluoroscopic appearances of various surgically implanted bioprosthetic valves. Because the sewing ring of the bioprosthetic valve, which is sutured to the native aortic annulus, provides the most reliable rigid anchor to hold the TAVI valve in place, it is important to know the relationship between the fluoroscopic markers and the location of the sewing ring (Figure 1).

Design. In certain valves (eg, the Sorin Mitraflow and the St. Jude Trifecta), the leaflets are sutured outside the stent posts. After a VIV procedure, the leaflets are pushed farther out and this can result in coronary obstruction, especially in patients with smaller aortic root dimensions.

Stentless Valves
During the past 2 decades, there have been a number of stentless valves that have been commercially available worldwide and each has specific recommendations regarding implantation options (Table 3).
device for secure placement because the stentless valves are neither heavily calcified like native aortic valves nor have a frame like a stented bioprosthesis. Hence, a 23-mm Sapien valve was used if the internal diameter of the annulus was <21 mm, and a 26-mm was used for an internal diameter between 21 mm and 24 mm. In the case of a borderline annulus, such as 21 mm, a larger prosthesis (26-mm Sapien) was preferred if the leaflets were not bulky and circumferential annular calcification was minimal. We feel that this degree of oversize is essential to achieve secure anchoring of the device and is a key factor in contributing to the technical success of the procedure in those patients with primary aortic regurgitation. Self-expanding TAVI devices such as the CoreValve may have an advantage in this situation and are preferred by a few operators.\textsuperscript{13}

**Fluoroscopic appearance.** None of the commercially available stentless valves are radio-opaque (Figure 2), which makes the procedure challenging, especially when the mode of failure is regurgitation.

**Design and implantation technique.** Unlike stented valves, stentless valves can be implanted using 1 of 3 techniques detailed in the Table 3. It is essential to know how the initial valve was implanted. In certain valves, such as CryoLife-O’Brien (CryoLife) and Pericarbon Freedom (Sorin), the suture lines are in proximity to the native coronary ostia, and VIV can result in coronary obstruction.

**VIV Positioning and Deployment: Stented Valves**

Stented bioprostheses provide good fluoroscopic landmarks for a VIV procedure. When the Sapien valve is used, the aim should be to place the valve at least 20% below the sewing ring of the bioprosthesis (Figure 1); and for the CoreValve, at least 6 mm below the sewing ring,\textsuperscript{7,12,19} which results in secure anchoring of the TAVI device. Details of VIV positioning for various types of bioprostheses have been reported elsewhere.\textsuperscript{7,12,19}

**VIV Positioning and Deployment: Stentless Valves**

In contrast to stented bioprostheses, implantation of the Sapien valve within a stentless valve poses a different set of technical challenges. Unlike native aortic valves, the failed stentless valves usually present with aortic regurgitation and are not heavily calcified. They also lack radio-opaque markers to facilitate positioning and a rigid frame to provide anchoring. In addition, the design and techniques of implantation of certain stentless valves may bring the coronary ostia in closer proximity to the annulus. To maximize precise deployment, we perform routinely a slow and gradual inflation of the prosthesis during a single short phase of rapid ventricular pacing as described by Pasic and colleagues.\textsuperscript{11}

We have also used 2 procedural modifications. In the first, in the presence of free regurgitation (n = 4), a guidewire was placed in the left main ostium to provide a distal landmark during deployment because it was impossible to determine the correct level of the aortic annulus (Figure 2, A). In the second, when the regurgitation was less or the valve was stenotic, we placed a pigtail catheter at the base of the sinus during implantation and injected contrast during gradual inflation of the device, which provided good delineation of the aortic annulus. The pigtail was withdrawn just before complete expansion of the Sapien valve (Figure 2, B). TEE is an important adjunct in these cases and can aid in correct placement of the Sapien valve.

**Role of BAV**

The majority of cases of VIV are now performed without a BAV.\textsuperscript{13} Degenerated bioprosthetic leaflets can be bulky and friable, and BAV can result in embolization of the debris and leaflet tears, resulting in severe aortic regurgitation. However, one can use BAV to determine risk of coronary occlusion after VIV and to locate the level of the annulus in the case of stentless valves and stented valves without radio-opaque markers (Figure 3).

**Hemodynamic Results**

**Uneven deployment.** A TAVI valve performs best when deployed circularly throughout its length. Thus, uneven expansion can result in poor hemodynamic performance. The internal diameter of the existing bioprosthesis at the level of

FIGURE 2. Valve-in-valve in a stentless valve. A, Fluoroscopy showing minimal calcification in a failed stentless valve (red arrow). B, Contrast injection during deployment of the Sapien device. Pigtail catheter is pulled back halfway through the deployment. C, In patients with severe regurgitation, a guidewire is placed in the left main to provide a landmark for correct deployment of Sapien valve (black arrow).
inflow is the most limiting diameter for TAVI valve expansion because the stent posts can be splayed outward. Uneven deployment can result in a conical or dumbbell-shaped deployment when using the Sapien valve (Figure 4). This problem will only be minimized when a wider range of sizes of TAVI valves becomes available to ensure an exact match.

**Residual gradient.** As a result of the placement of a valve inside another valve, there is a concern about significant residual gradients resulting from a “Russian nested doll” effect. Postprocedural gradients are in the range of 10 to 22 mm Hg in most series.\(^7,11,13,14\) Higher residual gradients are observed in smaller bioprostheses.\(^13\) Eggerbrecht and associates\(^25\) reported a trend of favorable hemodynamics when using the CoreValve in small bioprostheses (21 mm) compared with the Sapien valve, but the numbers were too small to draw definite conclusions. The main concern is in patients with a bioprosthesis with an internal diameter <19 mm. In our series, 4 patients with an internal diameter of ≤19 underwent VIV with a 23-mm Sapien valve. Two patients had higher residual mean gradients but continue to have excellent symptomatic improvement.

Similar observations have been reported by other authors, and hence VIV may be offered in such cases when there is no surgical option.\(^7,11,12,14\)

**Residual regurgitation.** Residual regurgitation can be the result of a paravalvular/perivalvular leak or a transvalvular leak. A transvalvular leak can be a result of underexpansion or an uneven expansion of the TAVI device.\(^13\) In our series, 6 patients had residual grade 1 leaks, all of which were paravalvular. Residual regurgitation resulting from a paravalvular leak is a significant problem when TAVI is used to treat the native valve, but most published series reporting experience with VIV have observed minimal residual regurgitation, similar to our experience.\(^7,11,13,14\) A degenerated bioprosthesis provides a circular annulus and less bulky leaflets, which allow an even expansion and better opposition of a TAVI device, thus resulting in a less degree of paravalvular leak when compared with a native stenotic aortic valve.

**Future Direction**

VIV implantation has been performed successfully in degenerated bioprostheses in the mitral, tricuspid, and pulmonary positions.\(^7,15,16\) Work is in progress from various groups to provide clinicians with robust bench data on this indication, and there is a possibility of trials for Conformite Europeene (CE) mark in the near future. Availability of more sizes of TAVI devices and specific TAVI devices for VIV will facilitate the procedure and ensure good long-term results.

**Study Limitations**

This is a large case series with short follow-up. Although we have shown feasibility and good short-term results by using a single device, larger studies and/or trials and long-term data are needed to understand efficacy of this treatment modality.
CONCLUSIONS
VIV is a useful alternative in selected patients who are at high risk for undergoing an open surgical procedure. Case selection is of paramount importance and should be discussed during an MDT. Patients with small bioprosthetic valves may be treated with VIV if the risk of conventional surgery is prohibitive. It is important to be familiar with the details of the in situ bioprostheses, including type, size, fluoroscopic appearance, and method of implantation, to have a successful outcome. Early results reveal improvement in hemodynamics and amelioration of symptoms, but longer follow-up with more patients is needed.

References

Discussion
Dr Mathew R. Williams (New York, NY). I would like to thank the American Association for Thoracic Surgery for the honor of discussing this paper and thank you, Dr Bapat, for sending the paper to me ahead of time. I had the pleasure of discussing a somewhat similar paper last year at this meeting, looking at VIV, and it is nice as a U.S. physician to now be discussing it with actually having experience with this procedure now that we have an approved system.

I will say that doing a transcatheter VIV is actually one of my favorite procedures and I think it is really remarkable how well these procedures do. With this procedure in particular, it gives us the advantages of the transcatheter procedure, a less invasive procedure with better recovery, but I think we also avoid some of the bad things that have been affiliated with transcatheter valves—namely, the paravalvular leak rate should probably be almost nothing in most cases, and in theory we might have a lower stroke rate, but we certainly don’t know that.

I am very impressed with your experience. It is still based on 23 patients, so I certainly don’t have anything to be critical of your presentation, but would rather ask you some questions related to how you conduct your clinical practice.

The first question is, I am wondering whether, given that this is such a great procedure for a degenerated bioprosthesis, have you changed your clinical practice in patients who are having surgical aortic valve replacements? Namely, are you putting tissue valves in younger patients? And if so, given what you discussed with the gradients, are you perhaps more aggressive about a root enlargement in somebody who you wouldn’t normally if you might be operating on an 80-year-old who you don’t expect to be operating on again?

The second question is about the approach. I am wondering why you did so many of these TA. I do understand that in some of the
first reports of this procedure it was recommended that it be done TA for better control, but I will be honest, I haven’t really understood that, and our approach has been just to do the procedures. If they have good access, we will do a TF; if they don’t, we will certainly do a TA.

And then the final question, which you alluded to a little bit, in the largest experience that was presented at the Transcatheter Valve Therapy meeting this year, there was a surprisingly high incidence, or a higher incidence than I expected—it’s still a low incidence—of coronary occlusion, which was most prominent with stentless valves and, in particular, actually, the Mitroflow valve, and I think 3 of your patients had the Mitroflow valve. I am wondering if you could comment on how you are addressing that potential fatal complication.

Dr Bapat. Thank you, Dr Williams, for your questions. My practice hasn’t changed, but patients are well informed now that we are doing a VIV procedure, and patients come to us saying they want a bioprosthetic valve because there is a good chance that in 10 to 15 years they will have a keyhole treatment by which we will take care of it. I give the choice to the patients regarding what kind of valve they are going to have, depending on their lifestyle and aversion to warfarin.

Yes, if I do a bioprosthetic valve in younger patients, my aim is to put a larger bioprosthesis. Having performed TAVI as well as an open aortic valve practice, that is going to be very important, because these patients are going to present at an age of maybe 75 or 80, and if I can at least put a 26 size Sapien valve, or whichever device is available at that time, it will definitely add 10 more years in each patient.

Your second question: Why TA? Absolutely. It was initially thought that it gives you better tactile feel, better control while you are inflating it slowly. Also if you remember with the RetroFlex 1 system, which lacked a nosecone crossing the valve, there were some catastrophic events such as leaflet tears, or sometimes the valve got stuck on the stent. And I think that is the only reason why units like ours have gone ahead and have just done TA. But we are changing with the availability of the NovaFlex system. And I completely agree with you that it should be taken the same way we treat the native aortic valve; the access should be determined by that.

And your last question about coronary obstruction, we are very cautious, and, as I mentioned in my presentation, with designs like Mitroflow, designs like Trifecta, but I think all the designs, especially in small valves, these patients tend to have small sinuses of Valsalva, and then we can do a BAV to check if there is a coronary obstruction. If I am correct, there are only 3 cases reported in the literature currently—2 with Mitroflow and 1 with Mosaic—that have led to coronary obstruction. However, I think in real life probably the incidence is much higher than that.

Dr Jahanzaib Idrees (Cleveland, Ohio). I have 1 question regarding younger patients in whom it would be more reasonable to place a mechanical valve. There are patients who are hesitant to get a mechanical valve and they don’t want to take Coumadin. So I am interested in knowing your perspective. Would you be confident in placing a bioprosthetic valve in that patient based on what you explained your results with so that maybe later on, if the valve wears off, you can do a VIV procedure? What would be your approach to convince that patient? Will you tell him to get a mechanical valve or would you tell him that a bioprosthetic valve may still be an option given the feasibility of a VIV procedure? What would be your approach in that regard?

Dr Bapat. As I said before, the approach hasn’t changed, because this should still be the result for high-risk patients. We don’t know how long these valves are going to last. As I showed you before, circularity is very important, and in TAVI procedures currently, you can’t control circularity in these patients. So I think options to the patients still remain the same. If they are young, they should decide whether they need to have a mechanical or bioprosthetic valve. I don’t make the choice for them.

Dr Ludwig Karl von Segesser (Lausanne, Switzerland). Congratulations for a nice series. You have not been very specific about the gradients in the smaller sizes of your valves. Could you specify about the 21 mm and the 19 mm especially?

Dr Bapat. Certainly. I think the residual gradients in all those patients were much, much higher. So we had a drop-off average gradient from 30 mm Hg to 9 mm Hg, but in these patients we had residual gradients, so mean gradients of at least 20 mm Hg. However, we undertook them as the last option, and the patients had very good symptomatic relief.

Dr Adrian Jeremy Levine (Stoke-on-Trent, UK). Very impressive work. Do you do balloon valvuloplasty for all valves of your late series? We started, like you, the first 1 or 2, not doing it, but now we have gone back and we balloon valvuloplasty all of ours. What about you?

Dr Bapat. We have gone the other way around. In fact, in our first case we did a BAV. I think the difference is because we do the TA. You don’t need to do a BAV. And the procedure is very short, only one pacing episode, and, again, I think doing a BAV—unless you are worried about coronary obstruction—I think there is no need to do a BAV.